Research in ASV therapy*

Get the big picture of adaptive servo-ventilation (ASV) therapy*, with an overview of updated guidelines and evidence highlighting its benefits for patients with central sleep apnoea (CSA).

A decade of evidence brings clarity to ASV

Since 2015 and the results of SERVE-HF,¹ the indications for use of ASV therapy have been revised. According to ERS consensus statement from 2017², ASV should be prescribed in cases of persistent CSA with AHI ≥ 15 per hour despite CPAP treatment, except in patients with symptomatic heart failure (NYHA 2-4) with reduced left ventricular ejection fraction (LVEF ≤ 45%), and moderate to severe CSA.

The 2025 ERS/ESRS³ statement confirms ASV is safe and effective for CSA patients with heart failure, except those with chronic, symptomatic heart failure (NYHA II–IV) and LVEF ≤ 45%, or moderate to severe central sleep apnoea. ASV may be considered for other CSA types, including treatment-emergent, drug-induced, neurological, or idiopathic CSA. For symptomatic patients with LVEF 30–45% unresponsive to CPAP, ASV should only begin in expert centres with close specialist monitoring.

In 2024, a French consensus and an experts’ statement on CSA in adult patients recommended waiting for them to use CPAP for one to three months before considering switching to ASV therapy in cases of persistent or emergent CSA.^4,5

The value of registries in ASV

Although randomised controlled trials (RCTs) are useful to assess safety and efficacy of a therapy, the lack of diversity in the selected patient population can lead to gaps in clinical knowledge.⁶ Real-world evidence, such as registries, assess outcomes in a non-selected population, representative of the day-to-day reality of sleep clinics. Following this logic, READ-ASV⁷, FACIL-VAA⁸ and FACE^9,10have provided valuable new insights.

Discover the ASV big picture

READ-ASV registry: indications and benefits of ASV in real life

READ-ASV⁷, launched in 2017, looked at the clinical benefits of ASV therapy in 801 patients in real-life settings.

The findings from the READ-ASV study⁷ reveal that ASV therapy is primarily used in clinical practice for patients with treatment-emergent central sleep apnoea (TE-CSA) and CSA with cardiovascular disease.

These patients experienced symptoms such as impaired quality of life, sleepiness, and low sleep quality, which were improved with ASV treatment, especially in individuals with pre-existing sleep disordered breathing (SDB).

FACE registry: adopting a phenotyping approach with ASV

The FACE registry^9,10 enrolled 503 heart failure patients from 2009 to 2018, with reduced ejection fraction before 2015, and then with preserved ejection fraction only after 2015. Among the 324 patients who underwent the two years follow-up, the analysis distinguished six phenogroups of patients and highlighted the existence of various phenotypes in chronic heart failure patients eligible for ASV therapy.

Results have shown that, compared to ASV non-users, three phenogroups had a better prognosis on morbi-mortality with ASV treatment:

Patients with HFmrEF/HFpEF (heart failure with mid-range ejection fraction/heart failure with preserved ejection fraction)
Patients with obstructive sleep apnoea (OSA) or CSA-OSA
Patients who are older, male and obese

The phenogroup that benefited the most included older, obese, hypoxic and hypertensive patients.

Download the full inforgraphic

What does real-world data tell us about ASV?

Real-world data from the registries^7-10 confirm that ASV therapy is safe and beneficial for quality of life and quality of sleep in the most prevalent phenotypes of symptomatic CSA and TE-CSA and combined OSA/CSA patients. In addition, major benefits were also reported in patients with combined heart failure with preserved LVEF>45% and CSA.^9,10

These registries highlighted the importance of addressing symptomatic individuals with SDB, and demonstrated that the effect of ASV can vary significantly depending on the phenotype of patients. One size does not fit all in the CSA population⁵: careful patient selection and phenotyping should be performed to ensure ASV is prescribed to patients most likely to benefit from therapy.

Discover the ASV big picture infographic

Identifying CSA patients using CPAP and switching them to ASV

An analysis of a PAP telemonitoring database identified three categories of CSA during CPAP treatment, all of which reduced therapy compliance and raised the risk of stopping treatment. The study revealed that transitioning patients from CPAP to ASV, particularly those with lower CPAP adherence possibly due to treatment-emergent CSA, resulted in enhanced adherence and device utilisation, along with a reduction in the apnoea-hypopnea index.

Learn more

This content is intended for health professionals only.

Please refer to the user (and clinical – if applicable) guides for relevant information related to any contraindications, warnings and precautions to be considered before and during use of the products.

*ASV therapy is contraindicated in patients with chronic, symptomatic heart failure (NYHA 2-4) with reduced left ventricular ejection fraction (LVEF ≤ 45%) and moderate to severe predominant central sleep apnoea.

**The figure is not intended as a general recommendation.

ASV: Adaptive-Servo Ventilation
BMI: Body Mass Index
CPAP: Continuous Positive Airway Pressure
CSA: Central Sleep Apnoea
ERS: European Respiratory Society
ESRS: European Sleep Research Society
FOSQ: Functional Outcomes of Sleep Questionnaire
HF: Heart Failure
HFmrEF: Heart Failure with Mid-Range Ejection Fraction (LVEF <40%)¹¹
HFpEF: Heart Failure with Preserved Ejection Fraction (LVEF 40–49%)¹¹
HFrEF: Heart Failure with Reduced Ejection Fraction (LVEF ≥50%)¹¹
LVEF: Left Ventricular Ejection Fraction
NYHA: New York Heart Association
OSA: Obstructive Sleep Apnoea
PSQI: Pittsburgh Sleep Quality Index
QoL: Quality of Life
TIA: Transient Ischaemic Attack

References

Cowie MR & al. Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure. New England Journal of Medicine, 2015 Sep 17;373(12):1095-105
Randerath et al. Definition, discrimination, diagnosis and treatment of central breathing disturbances during sleep ERJ 2017 49: 1600959 https://erj.ersjournals.com/content/49/1/1600959
Randerath WJ, Schiza SE, Arzt M, et al. European Respiratory Society and European Sleep Research Society statement on the treatment of central sleep apnoea with adaptive servo-ventilation. Eur Respir J 2025; 66: 2500263 [DOI: 10.1183/13993003.00263-2025]
Launois Rollinat & al. Consensus français sur les syndrome d’apnées et hypopnées centrales du sommeil (SAHCS) de l’adulte. Préambule : contexte et méthodologie utilisée, Médecine du Sommeil, 2024, ISSN 1769-4493, https://doi.org/10.1016/j.msom.2023.12.191
Randerath W, Baillieul S, Tamisier R. Central sleep apnoea: not just one phenotype. Eur Respir Rev. 2024;33(171):230141. DOI: 10.1183/16000617.0141-2023
Reynor A, McArdle N, Shenoy B, Dhaliwal SS, Rea SC, Walsh J, Eastwood PR, Maddison K, Hillman DR, Ling I, Keenan BT, Maislin G, Magalang U, Pack AI, Mazzotti DR, Lee CH, Singh B. Continuous positive airway pressure and adverse cardiovascular events in obstructive sleep apnea: are participants of randomized trials representative of sleep clinic patients? Sleep. 2022 Apr 11;45(4):zsab264. doi: 10.1093/sleep/zsab264. PMID: 34739082; PMCID: PMC9891109.
Arzt M et al. Effects of Adaptive Servo-Ventilation on Quality of Life: The READ-ASV Registry. Ann Am Thorac Soc. 2024 doi:10.1513/AnnalsATS.202310-908OC
Tamisier R, Philippe C, Prigent A, et al. Change in Sleep Quality Associated With Adaptive Servoventilation for Central Sleep Apnea: Six-Month Follow-Up of the Multicenter Nationwide French Cohort. Chest. 2025;167(4):1204-1217. doi:10.1016/j.chest.2024.12.015
Tamisier R et al. FACE study: 2-year follow-up of adaptive servo-ventilation for sleep-disordered breathing in a chronic heart failure cohort. Sleep Med. 2024 doi:10.1016/j.sleep.2023.07.014
Tamisier R et al. Adaptive servo ventilation for sleep apnoea in heart failure: the FACE study 3-month data. Thorax. 2022 doi:10.1136/thoraxjnl-2021-217205
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129–200.

Content update: 06/2026